Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could less dialysis be enough? study tests twice-weekly schedule for kidney patients

NCT ID NCT03874117

Completed Disease control Sponsor: Palo Alto Veterans Institute for Research Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at whether people with kidney failure who still have some kidney function can do well with only two dialysis sessions per week instead of the usual three. Fifty-eight patients each tried both schedules for four weeks. Researchers measured quality of life, symptoms, and cognitive function to compare the two approaches.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
hemodialysis (twice weekly vs thrice weekly)
What this could lead to
If successful, this could show that some patients with remaining kidney function can safely dialyze less often, improving quality of life.
What could go wrong
This is a small, short-term study (58 patients, 4 weeks per schedule) and may not prove long-term safety or apply to all dialysis patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMODIALYSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMODIALYSIS KIDNEY FAILURE, CHRONIC

Contacts and locations

Locations

  • Santa Clara Valley Medical Center

    San Jose, California, 95128, United States

  • Satellite HealthCare

    San Jose, California, 95128, United States

  • VA Palo Alto Health Care System

    Palo Alto, California, 94304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.